



HUTCHISON CHINA MEDITECH LIMITED

Results of Extraordinary General Meeting

London: Tuesday, 10 November 2015: Hutchison China MediTech Limited (“Chi-Med”) (AIM: HCM) today announces that the ordinary resolution and the special resolution put to its Extraordinary General Meeting held on 10 November 2015 (“EGM”) were duly passed.

The EGM follows the announcement by Chi-Med on 16 October 2015 of a potential issuance of new ordinary shares (the “Equity Raise”) in connection with a potential listing of American depository shares on the Nasdaq Stock Market. The resolutions passed at the EGM were required to be approved by the shareholders in order to enable Chi-Med to proceed with the Equity Raise and these authorities will expire at the next Annual General Meeting of Chi-Med.

The poll results of the resolutions were as follows:

Resolutions	Number of Votes (%) [*]		
	For	Against	Withheld [#]
Ordinary Resolution: To grant a general mandate to the directors of Chi-Med to issue additional ordinary shares.	44,990,518 (99.83997%)	72,114 (0.16003%)	0
Special Resolution: To disapply pre-emption rights.	44,989,418 (99.83753%)	73,214 (0.16247%)	0

^{*} Percentages rounded to 5 decimal places

[#] A vote withheld is not a vote in law and is not counted in the calculation of the proportion of the votes for and against a resolution.

As at the date of the EGM, the number of issued ordinary shares of Chi-Med was 56,533,118, which was the total number of ordinary shares entitling the holders to attend and vote on the ordinary resolution and special resolution proposed at the EGM.

Ends

Enquiries

Chi-Med Christian Hogg, CEO	Telephone:	+852 2121 8200
Panmure Gordon (UK) Limited Richard Gray Andrew Potts	Telephone:	+44 20 7886 2500
Citigate Dewe Rogerson Anthony Carlisle David Dible	Telephone: Mobile: Mobile:	+44 20 7638 9571 +44 7973 611 888 +44 7967 566 919

About Chi-Med

Chi-Med is a China-based, globally-focused healthcare group which researches, develops, manufactures and sells pharmaceuticals and health-related consumer products. Its Innovation Platform focuses on discovering and developing innovative therapeutics in oncology and autoimmune diseases for the global market. Its Commercial Platform manufactures, markets and distributes prescription drugs and consumer health products in China.

Chi-Med is majority owned by the multinational conglomerate CK Hutchison Holdings Limited (SEHK: 0001). For more information, please visit: www.chi-med.com.